Insulin FIASP (for “fast-acting insulin aspart”) is a new original insulin formulation that combines insulin aspart and two excipients, namely a vitamin (niacinamide) and an aminoacid (L-arginine), designed to increase the initial insulin absorption rate following subcutaneous injection, thereby promoting an earlier anti-hyperglycemic effect after meals. Its efficacy and safety profiles have been studied in the Onset clinical trial program. These first clinical studies have shown that using FIASP is associated with improved early post-prandial glycemic control compared to aspart alone in Type 1 and Type 2 diabetic subjects. It is expected that insulin FIASP will soon be available in Belgium.
Diabetes, aspart insulin, fast-acting insulin analogue
What is already known about the topic?
Ideally, the insulin injected just before the meal should act very quickly and have a duration of action limited to a few hours to mimic the postmeal physiological secretion of insulin of the normoglycemic subject. Fast analogous insulins are getting closer to this type of action without yet getting there perfectly.
What does this article bring up for us?
He describes the pharmacokinetic properties and the results of the clinical studies concerning a new fast-acting insulin analogue, FIASP (for "faster insulin aspart"), which combines insulin aspart with two excipients in order to increase the rate of insulin aspart. initial absorption after subcutaneous injection. This insulin will soon be available on the Belgian market.